CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 38 enrolled
Drug / intervention
d-cycloserinedrug
Likely dose
d-cycloserine 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00455702
NCT00455702Phase 4Completed
CompareCT.gov

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals

Massachusetts General Hospital·interventional·Posted Apr 4, 2007·Updated Aug 7, 2014

In Brief

A Phase 4 clinical trial evaluating d-cycloserine for Schizophrenia. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The study aims to assess the effects of single dose and repeated weekly dosing of 50mg d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients. The study will also examine the effects of 50mg d-cycloserine on positive symptoms and negative symptoms, as well as assess tolerability and side-effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 4, 2007
Enrollment StartJul 1, 2004
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.2 years ago

Interventions

d-cycloserinedrug

50mg dose d-cycloserine v placebo